Refine
Has Fulltext
- yes (14)
Is part of the Bibliography
- yes (14)
Document Type
- Journal article (14)
Language
- English (14)
Keywords
- adrenocortical carcinoma (4)
- CYP2W1 (2)
- adrenocortical cancer (2)
- carcinomas (2)
- prognosis (2)
- ACC (1)
- BIRC7 (1)
- COH29 (1)
- CXCR4 (1)
- CXCR7 (1)
Institute
- Medizinische Klinik und Poliklinik I (14)
- Pathologisches Institut (8)
- Comprehensive Cancer Center Mainfranken (2)
- Institut für Pharmakologie und Toxikologie (2)
- Center for Computational and Theoretical Biology (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Nuklearmedizin (1)
- Rudolf-Virchow-Zentrum (1)
- Urologische Klinik und Poliklinik (1)
Adrenocortical carcinoma (ACC) is a rare, aggressive cancer with still partially unknown pathogenesis, heterogenous clinical behaviour and no effective treatment for advanced stages. Therefore, there is an urgent clinical unmet need for better prognostication strategies, innovative therapies and significant improvement of the management of the individual patients. In this review, we summarize available studies on molecular prognostic markers and markers predictive of response to standard therapies as well as newly proposed drug targets in sporadic ACC. We include in vitro studies and available clinical trials, focusing on alterations at the DNA, RNA and epigenetic levels. We also discuss the potential of biomarkers to be implemented in a clinical routine workflow for improved ACC patient care.